The venture capital firm reported a challenging first half of 2025, with decreased revenue and a significant drop in cash position amid persistent market headwinds and limited capital availability.
The venture capital firm has acquired the assets of a novel antibiotic platform from a company in liquidation, with the potential to develop a product that could address the growing threat of antimicrobial resistance.
The venture capital firm will release its interim results on 30 September and hold an online investor presentation the same day.
The venture capital firm has entered into a licence agreement to share office space with a company owned by a substantial shareholder.
The asset management firm has announced changes to its major shareholdings.
The venture capital firm has released its annual report and announced its upcoming annual general meeting.
The deeptech and life sciences VC investment group announces its CEO and Executive Director have purchased additional shares in the company.
The venture capital firm reported widening losses and faces material uncertainty about its ability to continue as a going concern, despite recent fundraising efforts. Challenging market conditions and limited access to capital continue to pose significant headwinds.
The life sciences company reports Q1 2025 financial results and provides an update on its clinical programs and corporate developments.
The asset management firm has announced changes to its major shareholdings.